Development and ligand-protein interaction of small molecule anti-tumor FGFR inhibitors
10.16438/j.0513-4870.2016-0429
- VernacularTitle:小分子抗肿瘤FGFR抑制剂与FGFR蛋白的作用关系研究及研发进展
- Author:
Xiao-long LI
1
;
Rui QIU
1
;
Jue LI
1
;
Li HAI
1
;
Yong WU
1
Author Information
1. West China School of Pharmacy, Sichuan University, Chengdu 610041, China
- Publication Type:REVIEWS
- Keywords:
FGFs;
FGFRs;
small-molecular inhibitor;
anti-tumor;
ligand-protein interaction
- From:
Acta Pharmaceutica Sinica
2016;51(11):1689-
- CountryChina
- Language:Chinese
-
Abstract:
Fibroblast growth factor receptors (FGFRs) are in the superfamily of receptor tyrosine kinases' (RTKs). Fibroblast growth factors (FGFs) bind to FGFRs with high-affinity, involving in many biological processes, such as the regulation of organ development, angiogenesis, cell proliferation, migration and anti-apoptosis. The activating mutations and amplification of the FGFR gene, resulting in FGFR protein amplification, are closely associated with the development and progression of many malignancies in human. In recent years, various small molecule FGFR inhibitors with different chemical backbones are designed, synthesized, and mainly applied to the clinical anti-cancer research. This article is devoted to review of selective second generation of small molecule FGFR inhibitors that are currently used in clinical trials, and the interaction with the FGFR protein, in order to provide strategies to the design of small molecule FGFR inhibitors.
